Close 10 Sep 1505 scanned A
NIFTY 5023,477.80+0.20%
BANK NIFTY56,471.95+0.31%
INDIA VIX11.80-1.05%
MIDCAP 15022,904.25-0.38%
SMALLCAP 25018,433.40+0.01%
NEXT 5072,530.90-0.44%
BREADTH61%above 200-DMA
ADV / DEC558 / 939
NSE close 10 Sep

RUBICON

Rubicon Research
HealthcareLarge capRs 29,603 crRs 52.8 cr traded a day
Close on 10 September 2026
1,790.00
−1.13%
52-week range94% of the way up
577.251,860.60
Market cap
29,603 cr
P/E (TTM)
102.7×
industry 45×
EPS (TTM)
17.43
Net margin
15.9%
1 month
+8.2%
Below 52w high
3.9%
RSI (14)
56
Daily swing
4.3%
average true range
Volume
0.3×
vs 20-day average
Traded
Rs 53 cr
median day
Close200-day averageMaterial filing
5001,0001,500Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
236 sessions · hover for the filing behind a move

Key metrics

each ranked against every stock scanned tonight
Above the 200-day average
Top of the universe
+69.4%
One-year return
n/a
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
n/a
Below the 52-week high
from the highest close of the year
-3.8%
1 week
+0.81%
1 month
+8.25%
3 months
+33.14%
6 months
+133.10%
1 year

The read

written from the numbers on this page
The evidence leans constructive6 supporting, 1 against, 0 worth knowing

Supporting

  • trading 69% above its 200-day average
  • sitting at 94% of its 52-week range, with little overhead supply from trapped buyers
  • matches the market's strongest stocks, which has beaten the market by +0.59 points over 20 sessions across 51,498 past signals
  • 2 of the scans it matches have a positive measured record
  • 3 independent kinds of evidence agree today, which is uncommon
  • net margin has widened from 13.1% to 15.9% across four quarters

Against

  • priced at 103× earnings against an industry median of 45× — 130% above its peers

Worth knowing

  • nothing the data supports either way
What would change this read: a close below 1,056, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

from the filings and from the price, with the figure behind every line
Working1

Trading 69.4% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.

+69.4%
Needs watching
Nothing on this side tonight — not in the filings and not in the price.
Every figure here is computed — from the company’s own filings, or from its own closing prices. The wording is generated directly from the figures.

How it has performed

price return over each window, beside the median NSE stock over the same days
this stockmedian NSE stock, same window+0.8%+1.6 pt vs market1W+8.2%+9.3 pt vs market1M+33.1%+30.5 pt vs market3M+133.1%+116.5 pt vs market6M1Y

What the scans say today

5 of 47 matched on 10 Sep
RUBICON matches 5 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Recent filings

from the exchange, newest first
M&A filings were typically +0.18pt vs the market over the next 5 sessions (n=1,722) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Analyst call filings were typically +0.11pt vs the market over the next 5 sessions (n=4,339)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
41247651453413.1%15.3%14.9%15.9%Q2 FY26Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • net margin widened from 14.9% to 15.9%
  • revenue rose in 3 of the last 3 quarters

Going against it

  • nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
30 Jun · consolidated
534110855.1315.9%
Q4 FY26
31 Mar · consolidated
51499774.6614.9%
Q3 FY26
31 Dec · consolidated
47691734.4615.3%
Q2 FY26
30 Sep · consolidated
41272543.4913.1%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+11.1%
Versus 200-day average+69.4%
Below 52-week high-3.8%
Above 52-week low+210.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)55.7
Higher closes in last 51 of 5
Six-month return+133.10%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)4.28%
Volume versus 20-day0.3x
Median daily turnoverRs 52.8 cr

Peers

Healthcare · 68 classified companies
RUBICON trades at 102.7× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — more expensive than them, by 130%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA446,51037.5−4.27%+13.20%260.5
DIVISLAB250,12085.5+9.75%+54.92%372.1
TORNTPHARM166,86180.7+0.76%+34.85%128.2
APOLLOHOSP127,98258.9+3.52%+15.00%261.1
ZYDUSLIFE111,55625.5−7.24%+7.93%133.6
CIPLA110,94233.1−6.13%−10.95%108.3
LAURUSLABS105,07996.4+5.14%+115.20%353.0
MAXHEALTH101,08169.4+3.09%−11.35%184.0
AUROPHARMA96,00025.9+0.08%+49.31%122.2
DRREDDY95,44030.0−4.75%−12.17%122.9
LUPIN95,00717.1−8.91%+3.66%155.0
RUBICON29,603102.7+8.25%52.8
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
26 Aug1Closed at the very top of its range